Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-26,559
Closed -$1.96M 131
2026
Q1
$1.96M Sell
26,559
-190
-0.7% -$15.2K 0.04% 68
2025
Q4
$2.14M Sell
26,749
-625,580
-96% -$48.2M 0.04% 67
2025
Q3
$48.6M Sell
652,329
-476,761
-42% -$39.8M 1.09% 35
2025
Q2
$99.6M Sell
1,129,090
-66,622
-6% -$5.98M 3.09% 13
2025
Q1
$112M Buy
1,195,712
+50,350
+4% +$4.52M 3.52% 12
2024
Q4
$97.2M Buy
1,145,362
+69,002
+6% +$6.22M 3.38% 10
2024
Q3
$108M Buy
+1,076,360
New +$101M 3.73% 7

Other funds holding ALC

Antipodes Partners's ALC Position: Q2 2026 in Review

Antipodes Partners sold out of Alcon (ALC) in Q2 2026, closing a stake of 26,559 shares — an estimated $1.96M sold.

Antipodes Partners first reported a position in ALC in Q3 2024 and held it in 7 quarters. The position peaked at $112M in Q1 2025. 358 funds tracked by Wall St. Rank hold ALC as of Q2 2026.

  • Antipodes Partners reported no remaining Alcon position as of Q2 2026 after selling out during the quarter.
  • Antipodes Partners sold 26,559 Alcon shares in Q2 2026, an estimated $1.96M.
  • Antipodes Partners first reported a position in Alcon in Q3 2024 and held it in 7 quarters.
  • Antipodes Partners's Alcon position peaked at $112M in Q1 2025.
  • 358 funds tracked by Wall St. Rank held Alcon as of Q2 2026.

Based on Antipodes Partners's 13F filing for Q2 2026, filed 6 Aug 2026.